Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 every-6-weeks regimen in HER2-positive advanced breast cancer
ChiCTR2400092470Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anvatabart opadotin in breast cancer, sponsored by Henan Cancer Hospital. Primary endpoint: Objective response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
anvatabart opadotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400092470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092470.